Hematology/Oncology Fellowship Program

Program Description

We offer a fully integrated, three-year hematology and medical oncology program. For those pursuing eligibility for dual certification, the first 18 months of the program are dedicated to clinical education. It is during this time that a fellow participates in the evaluation and management of patients with solid tumors and hematologic malignancies. Fellows participate in a continuity clinic at M. D. Anderson Cancer Center in their first year and in a general oncology clinic at our affiliated county hospital in their second year. Other continuity clinics are also required in the second and/or third years to be board eligible in both hematology and medical oncology.

Our program also provides the opportunity for a two-year track leading to board eligibility (American Board of Internal Medicine) in the subspecialties of Medical Oncology or Hematology. The hematology track is designed to incorporate the diagnosis and management of a broad spectrum of hematologic disorders. At the conclusion of this track, the fellow is expected to be familiar with the natural history of hematologic and hemostatic disorders and hematologic malignancies. The medical oncology track incorporates training in the diagnosis and management of a broad spectrum of neoplastic disease. Each fellow is expected to be familiar with the natural history of the major and common human malignancies, and knowledgeable about appropriate diagnostic and therapeutic approaches.

To complete certification requirements, fellows are expected to develop concentrated expertise in one or more areas of clinical, basic, or translational research. Projects are reviewed on a regular basis and formal reports and presentations are required annually. It is anticipated that each fellow will leave this program as a competent, skilled oncologist with the ability to develop as an independent investigator in either a laboratory-based or clinically oriented research program.


The program is sponsored by The University of Texas Health Science Center at Houston, Department of Internal Medicine. (ACGME: 1404831423)

The sponsoring institution provides graduate medical education (GME) that facilitates fellows’ professional, ethical and personal development through curricula, evaluation, and fellow supervision to support safe and appropriate patient care. The Designated Institutional Official (DIO) in collaboration with the UT Graduate Medical Education Committee (GMEC), oversee all ACGME-accredited programs of the sponsoring institution. Collectively, they have the authority and responsibility for the oversight and administration of the sponsoring institution’s programs and responsibility for assuring compliance with ACGME common, specialty/subspecialty-specific program, and institutional requirements.


The University of Texas at Houston, MD Anderson Cancer Center Program, Hematology/Oncology Fellowship Program is accredited through the Accreditation Council for Graduate Medical Education (ACGME) #1554812150. www.acgme.org It is a private, nonprofit council that evaluates and accredits medical residency programs in the United States.

The ACGME was established in 1981 from a consensus in the academic medical community for an independent accrediting organization. Its forerunner was the Liaison Committee for Graduate Medical Education, established in 1972. It currently accredits over 8,700 programs. The mission of the ACGME is to improve health care by assessing and advancing the quality of resident physicians’ education through exemplary accreditation. Its member organizations are the American Board of Medical Specialties, American Hospital Association, American Medical Association, Association of American Medical Colleges and the Council of Medical Specialty Societies. Member organizations each appoint four members to the Board of Directors, which also includes two resident members, three public directors, a chair of the Council of Review Committees, one to four at large directors, and a non-voting federal representative.